Teyssou Elisa, Soulie Cathia, Fauchois Antoine, Palich Romain, Nouchi Agathe, Sayon Sophie, Abdi Basma, Wirden Marc, Katlama Christine, Pourcher Valérie, Marcelin Anne-Geneviève, Calvez Vincent
Laboratoire de Virologie, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, F-75013 Paris, France.
Service des maladies infectieuse, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, F-75013 Paris, France.
J Antimicrob Chemother. 2024 Jul 1;79(7):1673-1676. doi: 10.1093/jac/dkae164.
Resistance associated mutations (RAMs) are archived in the HIV reservoir and can re-emerge with an inappropriate ART use limiting treatment options. However, recent studies, using ultra-deep sequencing (UDS), showed a decrease of quasispecies harbouring RAMs, suggesting that recycling some antiretrovirals could be considered. The aim of this study was to characterize, in HIV treated PLWHIV, the M184V mutation decrease kinetics in proviral DNA and associated factors of M184V mutation clearance over time.
UDS was performed on HIV-DNA from blood cells at different time points to quantify the percentage of M184V positive quasispecies. The sequence reads were analysed with a minimum coverage set at 50 and an ambiguity filter at 5% or 2%.
At 2.5 years after the first time point, the M184V lost was observed in 50% of PLWHIV. Moreover, univariate analyses highlight that a higher nadir CD4 count and a lower zenith HIV1 RNA viral load were correlated with a faster clearance of the mutation. In multivariate analysis, a higher zenith was negatively associated with the M184V clearance at the 5% threshold. Interestingly, lamivudine/emtricitabine presence in the ART therapy regiment during the 5 years was not associated with the persistence of the M184V.
Our study provides new information concerning the clearance speed of M184V mutation over time in PLWHIV with fully suppressed viremia, opens the discussion about the duration needed to consider a lamivudine/emtricitabine recycling and reinforces the association of the nadir and zenith values with the M184V mutation clearance.
与耐药相关的突变(RAMs)存于HIV储存库中,在不恰当使用抗逆转录病毒疗法(ART)时可能重新出现,从而限制治疗选择。然而,近期使用超深度测序(UDS)的研究显示,携带RAMs的准种数量减少,这表明可以考虑重新使用某些抗逆转录病毒药物。本研究的目的是在接受治疗的HIV感染者(PLWHIV)中,描述前病毒DNA中M184V突变减少的动力学情况,以及随时间推移M184V突变清除的相关因素。
在不同时间点对血细胞中的HIV-DNA进行UDS,以量化M184V阳性准种的百分比。对序列读数进行分析,设置最小覆盖度为50,模糊度过滤为5%或2%。
在第一个时间点后的2.5年,50%的PLWHIV中观察到M184V丢失。此外,单因素分析表明,较低的最低点CD4细胞计数和较高的HIV-1 RNA病毒载量峰值与突变清除速度较快相关。在多因素分析中,较高的峰值在5%阈值时与M184V清除呈负相关。有趣的是,在5年的ART治疗方案中,拉米夫定/恩曲他滨的使用与M184V的持续存在无关。
我们的研究提供了有关病毒血症得到充分抑制的PLWHIV中M184V突变随时间清除速度的新信息,开启了关于考虑重新使用拉米夫定/恩曲他滨所需持续时间的讨论,并强化了最低点和峰值与M184V突变清除的关联。